STOCK TITAN

CRISPR Therapeutics (CRSP) Stock Price, News & Analysis

CRSP NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
37 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+12.9% close of August 19, 2026
1-year change
-20.7% closing prices, November 20, 2025 to November 20, 2026
1-month change
-21.6% closing prices, October 20, 2026 to November 20, 2026

Company Description

CRISPR Therapeutics AG (Nasdaq: CRSP) is a biopharmaceutical and gene editing company focused on developing transformative gene-based medicines for serious diseases. The company centers its work on CRISPR/Cas9 technology and related platforms to precisely edit genomic DNA and RNA. According to company disclosures, CRISPR Therapeutics has evolved from a pioneering research-stage organization into a gene editing leader, highlighted by the approval of CASGEVY, described as the world’s first CRISPR-based therapy for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.

CRISPR Therapeutics is headquartered in Zug, Switzerland, with a wholly owned U.S. subsidiary and research and development operations based in Boston, Massachusetts and San Francisco, California. Its shares trade on Nasdaq under the symbol CRSP. The company describes a broad and diversified pipeline spanning hemoglobinopathies, oncology, regenerative medicine, cardiovascular and autoimmune conditions, and rare diseases, supported by proprietary gene-editing and delivery technologies.

Core focus: gene editing medicines

The company’s work is rooted in the CRISPR/Cas9 system, which enables targeted changes to specific DNA sequences. CRISPR Therapeutics reports that it uses this technology both in ex vivo cell therapies, where cells are edited outside the body and reinfused, and in in vivo approaches, where editing occurs directly in the body using delivery platforms such as lipid nanoparticles (LNPs). In addition, the company has added a small interfering RNA (siRNA) pillar through a collaboration with Sirius Therapeutics, broadening its toolkit beyond DNA editing.

To expand its capabilities, CRISPR Therapeutics has developed the SyNTase™ editing platform, described as a novel, proprietary gene-editing technology designed to enable precise, efficient, and scalable gene correction, including single-dose in vivo gene correction in preclinical models. The company also highlights a proprietary LNP delivery platform for liver-directed in vivo gene editing.

Hemoglobinopathies and CASGEVY

A central program for CRISPR Therapeutics is CASGEVY® (exagamglogene autotemcel [exa-cel]), a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). In this therapy, a patient’s own hematopoietic stem and progenitor cells are edited at an erythroid-specific enhancer region of the BCL11A gene, which results in production of high levels of fetal hemoglobin (HbF) in red blood cells. Company materials state that CASGEVY has been shown to reduce or eliminate vaso-occlusive crises in SCD and transfusion requirements in TDT.

CRISPR Therapeutics notes that CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies in the United States, Great Britain or the United Kingdom, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Qatar, Canada, Switzerland, the United Arab Emirates, and Kuwait. The company and its partner Vertex Pharmaceuticals have also advanced pediatric development in patients aged 5 to 11 years through global Phase 3 studies, and Vertex is expected to lead regulatory submissions for this age group.

CASGEVY emerged from a long-standing collaboration between CRISPR Therapeutics and Vertex Pharmaceuticals, initiated in 2015 to discover and develop therapies using CRISPR/Cas9 technology. Under an amended collaboration agreement, Vertex leads global development, manufacturing, and commercialization of CASGEVY and shares program costs and profits worldwide with CRISPR Therapeutics. Vertex is described as the manufacturer and exclusive license holder of CASGEVY.

In vivo liver editing and cardiovascular/metabolic programs

CRISPR Therapeutics reports an extensive portfolio of in vivo liver-directed gene editing programs that leverage its proprietary LNP delivery platform. These programs focus on cardiovascular, cardiometabolic, and rare liver-related diseases where modulation of specific liver-expressed genes can alter disease risk or progression.

The lead in vivo program is CTX310®, an investigational CRISPR/Cas9 therapy designed to edit the ANGPTL3 gene in hepatocytes. ANGPTL3 encodes a protein that regulates triglyceride (TG) and low-density lipoprotein (LDL) levels. Company-reported Phase 1 data show dose-dependent, durable reductions in circulating ANGPTL3, TG, and LDL following a single-course intravenous infusion, and CTX310 is being advanced into Phase 1b clinical trials, with development prioritized in severe hypertriglyceridemia and mixed dyslipidemias.

Another clinical-stage in vivo candidate is CTX320™, which targets the LPA gene that encodes apolipoprotein(a), a major component of lipoprotein(a) [Lp(a)]. Elevated Lp(a) is described as a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events. CTX320 is in an ongoing Phase 1 clinical trial in patients with elevated Lp(a), and the company is also advancing a next-generation Lp(a) program, CTX321™, in preclinical development, incorporating an updated guide RNA for increased potency.

CRISPR Therapeutics is also progressing preclinical in vivo candidates such as CTX340™, targeting angiotensinogen (AGT) for refractory hypertension, and CTX450™, targeting ALAS1 for acute hepatic porphyria (AHP). These programs are reported to be in IND/CTA-enabling or preclinical stages, with preclinical data demonstrating gene editing, biomarker changes, and durability in animal models.

SyNTase™ platform and CTX460™ for alpha-1 antitrypsin deficiency

The company’s SyNTase™ editing platform is highlighted as a novel gene-editing approach designed for precise in vivo gene correction. The first investigational candidate from this platform is CTX460™, targeting the SERPINA1 gene mutation that causes alpha-1 antitrypsin deficiency (AATD). AATD is described as a genetic disorder most commonly caused by the Z allele (PiZ, E342K) in SERPINA1, leading to misfolded Z-AAT protein accumulation in the liver and insufficient functional M-AAT in circulation.

Preclinical data disclosed by CRISPR Therapeutics show that a single dose of CTX460 in animal models achieved high levels of DNA and mRNA correction in the liver, substantial increases in total serum AAT, and an M-AAT:Z-AAT ratio above 99%, with durable effects over several weeks. These findings are presented as preclinical proof-of-concept for single-dose in vivo gene correction using the SyNTase platform, and the company has stated its intention to move CTX460 into clinical trials.

Autoimmune disease and immuno-oncology: zugo-cel and cell therapies

CRISPR Therapeutics is also active in autoimmune disease and immuno-oncology through its allogeneic CAR T cell therapy programs. A key candidate is zugocaptagene geleucel (zugo-cel; formerly CTX112™), a wholly owned, allogeneic CAR T product targeting CD19. Zugo-cel is described as an off-the-shelf therapy that uses CRISPR/Cas9 for targeted gene knockout and CAR insertion to support immune evasion and T cell potency, administered after standard lymphodepletion without the need for HLA matching.

Zugo-cel is being investigated in Phase 1 basket trials for rheumatologic autoimmune diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis, as well as in a separate Phase 1 trial for autoimmune hematologic disorders such as immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA). Preliminary data reported by the company describe deep B-cell depletion, shifts toward naïve B-cell repertoires, and clinical improvement in early patients, with some SLE patients achieving drug-free remission measures.

In oncology, zugo-cel is being evaluated in a Phase 1/2 trial for relapsed or refractory B-cell malignancies, including large B-cell lymphoma and other CD19-positive subtypes. Company updates describe high overall and complete response rates at the recommended Phase 2 dose, along with observed CAR T cell expansion and reported safety profiles. CRISPR Therapeutics has also entered into a collaboration and clinical supply agreement with Lilly to evaluate zugo-cel in combination with pirtobrutinib in aggressive B-cell lymphomas.

The company has previously advanced other CAR T candidates such as CTX131™, targeting CD70, and has indicated that resources have been redirected toward programs with greater perceived long-term potential. CRISPR Therapeutics also notes that its autoimmune and immuno-oncology programs are supported by a wholly owned GMP manufacturing facility in Framingham, Massachusetts, which provides end-to-end production capabilities for its cell therapy portfolio.

siRNA collaboration with Sirius Therapeutics

Beyond DNA editing, CRISPR Therapeutics has established a strategic collaboration with Sirius Therapeutics to develop small interfering RNA (siRNA) therapies for thromboembolic and other serious diseases. The lead program in this collaboration is SRSD107, also referred to as CTX611™ in some company materials, a long-acting siRNA targeting coagulation Factor XI (FXI).

SRSD107/CTX611 is designed to inhibit FXI expression and modulate the intrinsic coagulation pathway, with the goal of providing anticoagulant and antithrombotic effects while potentially minimizing bleeding risk. Phase 1 trials in Australia and China reported strong, sustained reductions in FXI levels and prolonged activated partial thromboplastin time, with effects maintained for months after dosing. A Phase 2 trial in patients undergoing total knee arthroplasty (TKA) is underway in Europe to evaluate prevention of venous thromboembolism and to inform dose selection for future pivotal studies.

Under the collaboration, CRISPR Therapeutics and Sirius share development costs and profits for SRSD107, with CRISPR Therapeutics leading commercialization in the U.S. and Sirius leading in Greater China. The agreement also provides CRISPR Therapeutics with options to license additional siRNA programs from Sirius, extending its reach into RNA-based medicines.

Regenerative medicine and diabetes

CRISPR Therapeutics reports a regenerative medicine portfolio that includes efforts in Type 1 diabetes (T1D). The company has disclosed programs such as CTX211™ and next-generation candidates like CTX213™, which use induced pluripotent stem cell (iPSC)-derived, allogeneic, gene-edited beta islet cell precursors. Early clinical data from CTX211 showed detectable C-peptide levels 12 months after implantation, and these findings have informed the design of next-generation hypoimmune cell engineering approaches represented by CTX213.

According to company updates, CTX213 has demonstrated preclinical efficacy and is progressing toward clinical development, with the goal of achieving insulin independence in T1D patients without chronic immunosuppression. These programs illustrate how CRISPR Therapeutics applies gene editing to cell replacement strategies in addition to direct gene correction.

Business model, collaborations, and capital markets activity

CRISPR Therapeutics’ business model, as reflected in its public communications and SEC filings, combines internal research and development with collaborations and capital markets financing. The company highlights strategic partnerships with organizations such as Vertex Pharmaceuticals for CASGEVY and Sirius Therapeutics for siRNA programs, as well as a collaboration with Lilly around zugo-cel in oncology.

On the capital side, CRISPR Therapeutics has used an at-the-market equity program under an Open Market Sale Agreement with Jefferies LLC to offer and sell common shares. An October 2025 Form 8-K notes that the company filed a prospectus supplement to sell additional common shares with an aggregate offering price of up to a specified amount under a previously filed automatic shelf registration statement. The company’s 8-K filings also regularly furnish quarterly financial results and business highlights, reflecting ongoing operations as a publicly traded issuer.

Geographic footprint and sector classification

CRISPR Therapeutics AG is organized in Switzerland and lists its principal location as Zug, Switzerland in SEC filings. The company’s U.S. subsidiary, CRISPR Therapeutics, Inc., operates research and development facilities in Boston, Massachusetts and San Francisco, California. Within industry classification systems, the company is described as a biopharmaceutical or gene editing company and is associated with biological product manufacturing for therapeutic use.

Stock Performance

$39.50
+1.02%
+0.40
After hoursChange vs the $39.10 closeLast updated: at
-20.7%
Performance 1 year
97.0M
Shares outstanding As of October 30, 2026.

CRISPR Therapeutics (CRSP) closed at $39.10 on November 20, 2026. Over the past 12 months, the price has lost 20.7%.

See what a $1,000 investment in CRSP would be worth today

Average down calculator for CRSP

CRSP Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

CRISPR Therapeutics has 10 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 8 with negative movement. Key topics include clinical trial, earnings. View all CRSP news →

SEC Filings

CRISPR Therapeutics has filed 10 recent SEC filings, including 3 Form 4, 2 Form SCHEDULE 13G/A, 1 Form 3, 1 Form 144. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CRSP SEC filings →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
93,558
Shares Sold
7
Transactions
Most Recent Transaction
Kulkarni Samarth (Chief Executive Officer) sold 47,837 shares @ $49.78 on October 19, 2026

Insider selling at CRISPR Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

CRISPR Therapeutics generated $3.5M in revenue in FY2025, operating income reached -$664.6M, and net income was -$581.6M. Diluted earnings per share stood at -$6.47. The company generated -$345.0M in operating cash flow. The current ratio was 13.32, measuring current assets divided by current liabilities.

$3.5M
Revenue (FY2025)
-$581.6M
Net Income (FY2025)
-$345.0M
Operating Cash Flow

Upcoming Events

DEC
13
December 13, 2026 Clinical

ASH oral presentation

Oral presentation of zugo-cel Phase 1/2 LBCL data at ASH on Dec 13; 5:15 p.m. CST. Copies to be posted on company website after session.
MAR
01
March 1, 2031 Financial

Notes maturity

Maturity date for 2031 convertible senior notes (1.7308% coupon)
MAR
01
March 1, 2031 Financial

Convertible notes mature

Convertible senior notes due 2031 mature; $350M principal, initial purchaser option $52.5M.

CRISPR Therapeutics has 3 upcoming scheduled events. The next event, "ASH oral presentation", is scheduled for December 13, 2026 (in 21 days). 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the CRSP stock price.

Short Interest History

Last 12 Months

Short interest in CRISPR Therapeutics (CRSP) currently stands at 17.2 million shares, up 4.5% from the previous reporting period, representing 18.7% of the float. Since November 2025, short interest has decreased by 23.4%.

Days to Cover History

Last 12 Months

Days to cover for CRISPR Therapeutics (CRSP) currently stands at 13.1 days, up 28% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 41.5%. Across the settlements charted above, it has ranged from 7.6 to 16.5 days.

CRSP Company Profile & Sector Positioning

CRISPR Therapeutics (CRSP) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing CRSP often look at related companies in the same sector, including Ionis Pharmaceuticals, Inc. (IONS), Tango Therapeutics, Inc. (TNGX), Xenon Pharmaceuticals Inc (XENE), Disc Medicine, Inc. (IRON), and Viridian Therapeutics, Inc. (VRDN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CRSP's relative position within its industry.

Frequently Asked Questions

The current stock price of CRISPR Therapeutics (CRSP) is $39.50 in after-hours trading as of November 20, 2026.

The market cap of CRISPR Therapeutics (CRSP) is approximately $3.8B. Learn more about what market capitalization means .

The FY2025 revenue of CRISPR Therapeutics (CRSP) is $3.5M, from its most recent completed fiscal year.

The FY2025 net income of CRISPR Therapeutics (CRSP) is -$581.6M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of CRISPR Therapeutics (CRSP) is -$6.47 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of CRISPR Therapeutics (CRSP) is -$345.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of CRISPR Therapeutics (CRSP), current assets divided by current liabilities, was 13.32 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of CRISPR Therapeutics (CRSP) is -$664.6M for FY2025, its most recent completed fiscal year. Learn about operating income.

CRISPR Therapeutics AG focuses on developing gene-based medicines using CRISPR/Cas9 and related technologies. Its programs include ex vivo cell therapies, in vivo gene editing candidates, and siRNA-based therapies targeting serious diseases such as hemoglobinopathies, cardiovascular and autoimmune disorders, oncology indications, regenerative medicine applications, and rare genetic conditions.

CASGEVY (exagamglogene autotemcel [exa-cel]) is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. A patient’s own hematopoietic stem and progenitor cells are edited at an erythroid-specific enhancer region of the BCL11A gene, leading to increased fetal hemoglobin production in red blood cells. Company reports indicate this can reduce or eliminate vaso-occlusive crises in sickle cell disease and transfusion requirements in beta thalassemia.

Company disclosures state that CASGEVY is approved for eligible patients 12 years and older with sickle cell disease or transfusion-dependent beta thalassemia in the United States, Great Britain or the United Kingdom, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Qatar, Canada, Switzerland, the United Arab Emirates, and Kuwait.

CRISPR Therapeutics and Vertex Pharmaceuticals entered a strategic research collaboration in 2015 to discover and develop therapies using CRISPR/Cas9 technology. CASGEVY is the first approved therapy from this collaboration. Under an amended agreement, Vertex leads global development, manufacturing, and commercialization of CASGEVY and shares program costs and profits worldwide with CRISPR Therapeutics, and Vertex is described as the manufacturer and exclusive license holder of CASGEVY.

CTX310 is an investigational in vivo CRISPR/Cas9 therapy delivered by lipid nanoparticles to edit the ANGPTL3 gene in the liver, with the goal of durably lowering triglycerides and LDL cholesterol in patients with severe or refractory dyslipidemia. CTX320 is another in vivo program targeting the LPA gene, which encodes apolipoprotein(a), for patients with elevated lipoprotein(a), a genetic risk factor for cardiovascular events. Both are in clinical development according to company updates.

SyNTase is a proprietary gene-editing platform described by CRISPR Therapeutics as enabling precise, efficient, and scalable gene correction, particularly for in vivo applications. The first candidate from this platform, CTX460, targets the SERPINA1 mutation that causes alpha-1 antitrypsin deficiency. Preclinical data show high levels of gene and mRNA correction and increased functional AAT protein in disease models following a single dose.

Zugocaptagene geleucel (zugo-cel; formerly CTX112) is a wholly owned, allogeneic CAR T cell therapy targeting CD19. It is being studied in Phase 1 basket trials for autoimmune rheumatologic diseases such as systemic lupus erythematosus, systemic sclerosis, and inflammatory myositis, and in a separate Phase 1/2 trial for relapsed or refractory B-cell malignancies, including large B-cell lymphoma and other CD19-positive lymphomas.

Through a collaboration with Sirius Therapeutics, CRISPR Therapeutics is co-developing SRSD107, also referenced as CTX611, a long-acting siRNA targeting coagulation Factor XI for thromboembolic and clotting-related disorders. Phase 1 data have shown deep and sustained reductions in FXI levels, and a Phase 2 trial in patients undergoing total knee arthroplasty is underway in Europe. The collaboration includes cost and profit sharing and options for CRISPR Therapeutics to license additional siRNA programs.

CRISPR Therapeutics reports regenerative medicine programs focused on Type 1 diabetes, including CTX211 and a next-generation candidate CTX213. These programs use induced pluripotent stem cell-derived, allogeneic, gene-edited beta islet cell precursors. Early clinical data from CTX211 showed detectable C-peptide levels 12 months after implantation, and CTX213 has demonstrated preclinical efficacy as a hypoimmune cell therapy candidate.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland. Its wholly owned U.S. subsidiary, CRISPR Therapeutics, Inc., operates research and development facilities in Boston, Massachusetts and San Francisco, California, according to company statements and SEC filings.

As a Nasdaq-listed company, CRISPR Therapeutics accesses capital through equity offerings and maintains cash, cash equivalents, and marketable securities. An October 2025 Form 8-K notes that the company filed a prospectus supplement under an existing shelf registration statement to offer and sell additional common shares through Jefferies LLC under an Open Market Sale Agreement, illustrating its use of at-the-market equity programs.